Trial Profile
A Multicenter, Open-Label Extension Study of WVE-210201 in Patients Previously Enrolled in WVE-DMDX51-001
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Suvodirsen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors WaVe life Sciences
- 02 Mar 2020 According to a WaVe life Sciences media release, the company plans to present additional findings from phase 1 open-label extension study at the 2020 MDA Clinical and Scientific Conference in Orlando, Florida, which will take place from March 20 through March 25, 2020.
- 16 Dec 2019 According to a WaVe life Sciences media release, Patients will have a final follow-up visit, but no further doses will be administered, and patients will no longer undergo muscle biopsies.
- 16 Dec 2019 Status changed from recruiting to discontinued, according to a WaVe life Sciences media release.